Nightingale Health
1.805 EUR -2.96%Nightingale Health operates in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes platforms and services in blood tests that are used for disease prevention purposes. In addition to the main business, service and associated ancillary services are also offered. The business is run globally with the largest presence in Europe.
Log in to see the recommendation and risk by Inderes
Latest research
Extensive report
Analyst
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Cor Group Oy | 10.2 % | 12.7 % |
Antti Kangas | 8.8 % | 21.8 % |
Premium
This content is for our Premium customers only.
Insider Transactions
Insider | Date | Total value |
---|---|---|
Ilkka Laurila | 12.10.2023 | 8,831EUR |
Tuukka Paavola | 29.09.2023 | 7,730EUR |
Premium
This content is for our Premium customers only.
Forum updates
Income statement
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Revenue | 1.8 | 2.3 | 2.3 | 4.2 | 4.7 | 8.7 | 15.1 | 24.9 |
growth-% | -13.0 % | 29.4 % | 0.3 % | 80.8 % | 12.8 % | 85.0 % | 72.7 % | 65.0 % |
EBITDA | -3.1 | -7.3 | -9.4 | -12.9 | -9.8 | -9.6 | -6.4 | -0.7 |
EBIT (adj.) | -3.3 | -8.6 | -13.6 | -18.5 | -17.8 | -17.6 | -13.1 | -6.7 |
EBIT | -3.3 | -9.8 | -13.6 | -18.5 | -17.8 | -17.6 | -13.1 | -6.7 |
Profit before taxes | -3.7 | -9.7 | -16.2 | -18.2 | -16.3 | -16.7 | -12.4 | -6.3 |
Net income | -3.7 | -9.7 | -16.1 | -18.2 | -16.4 | -16.7 | -11.8 | -5.9 |
EPS (adj.) | -0.21 | -0.23 | -0.30 | -0.27 | -0.27 | -0.19 | -0.10 | |
growth-% | ||||||||
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dividend ratio |
Login required
This content is only available for logged in users
Profitability and return on capital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | -174.9 % | -316.7 % | -405.9 % | -308.4 % | -208.5 % | -110.2 % | -42.6 % | -2.8 % |
EBIT-% (adj.) | -187.6 % | -375.0 % | -589.5 % | -442.9 % | -377.5 % | -201.9 % | -87.0 % | -26.9 % |
EBIT-% | -187.6 % | -423.2 % | -589.5 % | -442.9 % | -377.5 % | -201.9 % | -87.0 % | -26.9 % |
ROE | -62.3 % | -15.0 % | -13.7 % | -17.4 % | -18.4 % | -23.0 % | -20.3 % | -12.0 % |
ROI | -26.1 % | -13.7 % | -11.1 % | -17.1 % | -19.4 % | -23.1 % | -20.8 % | -12.3 % |
Login required
This content is only available for logged in users
Valuation
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Share price (EUR) | 3.68 | 1.02 | 1.12 | 1.81 | 1.81 | 1.81 | 1.81 | |
Shares | 60.5 | 60.9 | 60.9 | 60.9 | 60.9 | 60.9 | 60.9 | |
Market cap | 222.5 | 61.9 | 68.0 | 110.0 | 110.0 | 110.0 | 110.0 | |
Enterprise value | 114.6 | -28.9 | -10.0 | 44.1 | 57.8 | 70.4 | 76.5 | |
EV/S | - | 49.7 | - | - | 9.4 | 6.6 | 4.7 | 3.1 |
EV/EBITDA | - | - | 3.1 | 0.8 | - | - | - | - |
EV/EBIT (adj.) | - | - | 2.1 | 0.5 | - | - | - | - |
EV/EBIT | - | - | 2.1 | 0.5 | - | - | - | - |
P/E (adj.) | - | - | - | - | - | - | - | - |
P/E | - | - | - | - | - | - | - | - |
P/B | - | 1.8 | 0.6 | 0.7 | 1.4 | 1.7 | 2.1 | 2.4 |
P/S | - | 96.5 | 26.8 | 16.3 | 23.3 | 12.6 | 7.3 | 4.4 |
Dividend yield | ||||||||
Equity ratio | 23.2 % | 88.5 % | 89.8 % | 91.2 % | 88.7 % | 84.0 % | 78.6 % | 71.7 % |
Gearing ratio | 87.6 % | -87.4 % | -81.3 % | -80.1 % | -81.3 % | -81.2 % | -75.4 % | -71.8 % |
Login required
This content is only available for logged in users
Quarter data
Q3/23 | Q4/23 | 2023 | Q1/24 | Q2/24 | Q3/24e | Q4/24e | 2024e | Q1/25e | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 1.9 | 4.2 | 1.7 | 3.0 | 4.7 | ||||
EBITDA | -7.4 | -12.9 | -5.3 | -4.5 | -9.8 | ||||
EBIT | -9.9 | -18.5 | -9.3 | -8.5 | -17.8 | ||||
Profit before taxes | -9.7 | -18.2 | -8.5 | -7.8 | -16.3 | ||||
Net income | -9.7 | -18.2 | -8.5 | -7.8 | -16.4 |
Login required
This content is only available for logged in users
Inside information: Nightingale Health achieves one of its business targets for this financial year by winning contracts in medical research with a total contract value of at least EUR 3.2 million
Nightingale opens its own laboratory in the US and wins a new customer
Join Inderes community
Don't miss out - create an account and get all the possible benefits